Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Kinders

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Leukemia Research|September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemiaJonathan A Webster, Raoul Tibes, Larry Morris, et al.
Molecular Interventions|January 18, 2008
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practiceRobert Kinders, Ralph E Parchment, Jay Ji, et al.
Cancer Research|July 29, 2011
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomasShivaani Kummar, Alice Chen, Jiuping Ji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignanciesShivaani Kummar, Robert Kinders, Martin E Gutierrez, et al.
JCO Precision Oncology|July 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid TumorsGeraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers NetworkGuray Akturk, Edwin R Parra, Evisa Gjini, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Leukemia Research|September 29, 2017
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemiaJonathan A Webster, Raoul Tibes, Larry Morris, et al.
Molecular Interventions|January 18, 2008
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practiceRobert Kinders, Ralph E Parchment, Jay Ji, et al.
Cancer Research|July 29, 2011
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomasShivaani Kummar, Alice Chen, Jiuping Ji, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2009
Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignanciesShivaani Kummar, Robert Kinders, Martin E Gutierrez, et al.
JCO Precision Oncology|July 16, 2025
Safety and Tolerability of Berzosertib, an Ataxia-Telangiectasia-Related Inhibitor, and Veliparib, an Oral Poly (ADP-ribose) Polymerase Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid TumorsGeraldine O'Sullivan Coyne, Khanh T Do, Shivaani Kummar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers NetworkGuray Akturk, Edwin R Parra, Evisa Gjini, et al.
Pageof 2